Dasher Neuroscience has successfully completed patient enrollment for its global Phase 2 trial of YA-101, aimed at treating Multiple System Atrophy. Results are anticipated in early 2027.

Dasher Neuroscience has completed patient recruitment for the Phase II clinical trial of YA-101, aimed at treating multiple system atrophy, a rare neurodegenerative disorder.

Dasher Neuroscience has completed patient enrollment for its Phase 2 trial of YA-101, an AI-developed treatment for Multiple System Atrophy, aiming for commercialization.

A recent study reveals that a new oral drug may slow down the progression of multiple system atrophy by managing iron levels in the brain.

At the upcoming International MSA Congress in Boston, Lundbeck will share vital pipeline data and patient insights from its AMULET trial, focusing on treatment for multiple system atrophy.

Yoda Therapeutics has successfully dosed its first patient in the Phase 2 trial of YA-101 for multiple system atrophy, a significant advancement for this rare disease.

The market for multiple system atrophy is on the rise, promising new therapies to meet unmet needs and improving patient outcomes by 2034.